Rafferty Asset Management, LLC Chemo Centryx, Inc. Transaction History

Rafferty Asset Management, LLC

$28.9 Billion
Q3 2024

Shares

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$22.17 - $51.8 $394,005 - $920,589	-17,772 Reduced 11.66%	134,596 $6.95 Million
Q2 2022 Aug 12, 2022	SELL	$15.36 - $27.51 $1.12 Million - $2.01 Million	-73,036 Reduced 32.4%	152,368 $3.78 Million
Q1 2022 May 13, 2022	BUY	$22.22 - $39.12 $1.52 Million - $2.67 Million	68,183 Added 43.37%	225,404 $5.65 Million
Q4 2021 Feb 10, 2022	SELL	$18.38 - $40.5 $824,434 - $1.82 Million	-44,855 Reduced 22.2%	157,221 $5.72 Million
Q3 2021 Nov 10, 2021	SELL	$13.18 - $19.83 $159,346 - $239,744	-12,090 Reduced 5.65%	202,076 $3.46 Million
Q2 2021 Aug 10, 2021	BUY	$9.59 - $50.88 $1.5 Million - $7.96 Million	156,386 Added 270.66%	214,166 $2.87 Million
Q1 2021 May 10, 2021	BUY	$49.53 - $68.4 $2.1 Million - $2.9 Million	42,425 Added 276.29%	57,780 $2.96 Million
Q4 2020 Feb 10, 2021	SELL	$47.25 - $65.16 $1.22 Million - $1.69 Million	-25,920 Reduced 62.8%	15,355 $951,000
Q3 2020 Nov 13, 2020	BUY	$46.35 - $61.69 $1.23 Million - $1.64 Million	26,605 Added 181.36%	41,275 $2.26 Million
Q2 2020 Aug 07, 2020	BUY	$38.58 - $65.07 $565,968 - $954,576	14,670 New	14,670 $844,000
Q1 2020 May 15, 2020	SELL	$32.73 - $50.78 $382,842 - $593,973	-11,697 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$6.81 - $39.55 $79,656 - $462,616	11,697 New	11,697 $463,000
Q3 2019 Nov 14, 2019	SELL	$6.47 - $8.96 $571,016 - $790,773	-88,256 Closed	0 $0
Q2 2019 Aug 09, 2019	BUY	$8.31 - $14.85 $733,407 - $1.31 Million	88,256 New	88,256 $821,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.